Nurix Therapeutics NRIX
NASDAQ NRIX
$22.99 -0.35 (-1.50%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nurix Therapeutics (NRIX) Return on Sales [ROS] (2019 - 2026)

Updated

Nurix Therapeutics (NRIX) recorded Return on Sales [ROS] of -1041.73% in fiscal Q2 2026 (quarter ended May 31, 2026), down 932.05 percentage points from -109.68% a year earlier but up 437.71 percentage points from the prior quarter.

Analysis

Nurix Therapeutics (NRIX) Return on Sales [ROS] (2019 - 2026) Analysis & Trends

On a TTM basis, Nurix Therapeutics' Return on Sales [ROS] came in at -982.37% as of May 31, 2026, down 721.62 percentage points year-over-year; for FY2025 (ended Nov 30, 2025), it was -340.16%, up 50.36 percentage points from FY2024.

  • Annual Return on Sales [ROS] has a five-year change of +24.50 percentage points (FY2020 to FY2025).
  • Across earlier fiscal years, Return on Sales [ROS] came in at -390.52% in FY2024 (-189.11 pp), -201.41% in FY2023 (+274.59 pp), -476.01% in FY2022 (-79.75 pp) and -396.26% in FY2021 (-31.59 pp).
  • Quarterly Return on Sales [ROS] has ranged from -1479.45% in fiscal Q1 2026 to -87.25% in fiscal Q2 2023 over the past five years.
  • On a year-over-year basis, Return on Sales [ROS] has declined for four consecutive quarters, with an average year-over-year change of -387.63 percentage points over the last eight quarters.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 418.77 percentage points in fiscal Q4 2023, against a drop of 1138.78 percentage points in fiscal Q1 2026 at the low end.
  • Per Business Quant, the preceding three fiscal quarters came in at -1479.45% (Q1 2026), -612.03% (Q4 2025) and -1157.65% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 28.21%
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 37.86%
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 32.97%
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 20.57%
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 34.95%
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -133.21%
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn 28.37%
10 Nurix Therapeutics 2.42 Bn 414.36 Mn - -1,041.73%
Historic Data

Historic Data

Download Data
DateValue
May 31, 2026 -1,041.73%
Feb 28, 2026 -1,479.45%
Nov 30, 2025 -612.03%
Aug 31, 2025 -1,157.65%
May 31, 2025 -109.68%
Feb 28, 2025 -340.67%
Nov 30, 2024 -486.73%
Aug 31, 2024 -433.83%
May 31, 2024 -401.42%
Feb 29, 2024 -272.65%
Nov 30, 2023 -299.06%
Aug 31, 2023 -216.67%
May 31, 2023 -87.25%
Feb 28, 2023 -338.60%
Nov 30, 2022 -717.82%
Aug 31, 2022 -432.93%
May 31, 2022 -399.89%
Feb 28, 2022 -444.28%
Nov 30, 2021 -513.16%
Aug 31, 2021 -282.84%
API Access

Nurix Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NRIX&period=max&api_key=YOUR_API_KEY